In 2009, routine prostate cancer screening using a prostate-specific antigen (PSA) test was described as “the controversy that refuses to die.”1(p1351) Unfortunately, 10 years later, the controversy is still alive and thriving.2 Clinical trials have failed to resolve whether or to what degree screening using PSA tests help reduce prostate cancer–specific mortality, and it has long been clear that PSA screening tests increase the diagnosis of low-risk cancers and can lead to patient harm from potentially unnecessary biopsies and cancer treatment. As a result, many expert groups recommend shared decision-making (SDM) and informed patient choice for routine prostate cancer screening.3,4
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Scherer LD, Lin G. Decision Aids for Prostate Cancer Screening—The True Potential Remains Unknown. JAMA Intern Med. 2019;179(8):1082–1083. doi:10.1001/jamainternmed.2019.0753
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.